PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations

Código QR

PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations

Abstract PCC-0208027 is a novel tyrosine kinase inhibitor that has a strong inhibitory effect on epidermal growth factor receptor (EGFR)- or HER2-driven cancers. The aim is to assess the anti-tumor activity of PCC0208027 and related mechanisms in non-small cell lung cancer (NSCLC). We examined the a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qiuju Dong, Pengfei Yu, Liang Ye, Jianzhao Zhang, Hongbo Wang, Fangxia Zou, Jingwei Tian, Hiroshi Kurihara
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/316acfb7beae4c10bb5699957babc6e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Liesbeth M. Hondelink, MD, et al.
Publicado: (2021)

High expression of hypoxia inducible factor 1α related with acquired resistant to EGFR tyrosine kinase inhibitors in NSCLC
por: Qian Jin, et al.
Publicado: (2021)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
por: Okimoto RA, et al.
Publicado: (2015)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Ilana Schlam, et al.
Publicado: (2021)

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
por: Jeet Gandhi, et al.
Publicado: (2009)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Sangyong Jung, et al.
Publicado: (2021)

Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
por: Yu D, et al.
Publicado: (2021)

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
por: Natalia J. Gurule, et al.
Publicado: (2021)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
por: Bin Zou, et al.
Publicado: (2017)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
por: Rajeswara Rao Arasada, et al.
Publicado: (2018)

In Vitro and In Vivo Characterization of PCC0104005, a Novel Modulator of Serotonin-Dopamine Activity, as an Atypical Antipsychotic Drug
por: Yanan Xu, et al.
Publicado: (2018)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
por: Zhang SS, et al.
Publicado: (2021)

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway
por: Simona Taverna, et al.
Publicado: (2017)

EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1
por: Toshinori Ando, et al.
Publicado: (2021)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Hyun Woo Lee, et al.
Publicado: (2020)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
por: João M. Fernandes Neto, et al.
Publicado: (2020)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Motohiro Tamiya, et al.
Publicado: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
por: Diana B. Peckys, et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: C. I. Edvard Smith, et al.
Publicado: (2021)

Small molecule tyrosine kinase inhibitors in pancreatic cancer
por: Sachin Gupta, et al.
Publicado: (2008)

Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.
por: Hong-bing Liu, et al.
Publicado: (2013)

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity
por: Takahiro Yoshizawa, et al.
Publicado: (2021)

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί
por: Jeon-Soo Lee, et al.
Publicado: (2021)

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
por: Young H Lee, et al.
Publicado: (2021)

Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
por: Nan Jin, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

Neurotrophin receptor tyrosine kinases regulated with near-infrared light
por: Anna V. Leopold, et al.
Publicado: (2019)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
por: Mikkel G. Terp, et al.
Publicado: (2021)

Sensitive genotyping of mutations in the EGFR gene from NSCLC patients using PCR-GoldMag lateral flow device
por: Xian-Ying Li, et al.
Publicado: (2017)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
por: Junjie GU, et al.
Publicado: (2021)

Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
por: Stratmann JA, et al.
Publicado: (2019)

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report
por: Masatomo Ueda, et al.
Publicado: (2021)

Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients
por: Mohamed A. Ismail, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Yen-Hsiang Huang, et al.
Publicado: (2021)